跨膜蛋白79在肝细胞癌中的表达及临床意义

doi:10.3969/j.issn.1004-616x.2023.06.004

癌变·畸变·突变 ›› 2023, Vol. 35 ›› Issue (6): 426-430.doi: 10.3969/j.issn.1004-616x.2023.06.004

跨膜蛋白79在肝细胞癌中的表达及临床意义

朱文标¹, 丘波², 谢寿城¹, 肖焕钦¹, 刘高敏³

1. 汕头大学医学院梅州临床学院/梅州市人民医院病理科, 广东梅州 514031;
2. 嘉应学院分子生物学中心实验室/病理教研室, 广东梅州 514031;
3. 汕头大学医学院梅州临床学院/梅州市人民医院肝胆外科, 广东梅州 514031

收稿日期:2023-09-19 修回日期:2023-10-19 出版日期:2023-11-30 发布日期:2023-12-09
通讯作者: 刘高敏
作者简介:朱文标，E-mail：piaoran7907@126.com。
基金资助:
广东省医学科研基金(B2021140)；梅州市科技计划项目(2020B092)；梅州市人民医院科研培育项目(PY-C2020008；PY-C2022038)

Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma

ZHU Wenbiao¹, QIU bo², XIE Shoucheng¹, XIAO Huanqin¹, LIU Gaomin³

1. Department of Pathology, Meizhou Clinical Institute of Shantou University Medical College/Meizhou People's Hospital, Meizhou 514031;
2. Molecular Biology Laboratory/Department of Pathology, Jiaying University, Meizhou 514031;
3. Department of Hepatobiliary Surgery, Meizhou Clinical Institute of Shantou University Medical College/Meizhou People's Hospital, Meizhou 514031, Guangdong, China

Received:2023-09-19 Revised:2023-10-19 Online:2023-11-30 Published:2023-12-09

摘要/Abstract

摘要： 目的：探讨跨膜蛋白79(TMEM79)在肝细胞癌(HCC)组织中的表达及其与患者临床病理指标及预后的关系，评估其对Ia-IIa期HCC切除后复发转移及生存情况的预测价值。方法：收集行根治性手术切除的HCC病例95例，采用免疫组织化学方法检测HCC肿瘤组织与配对非肿瘤组织中TMEM79蛋白的表达，分析TMEM79蛋白表达与患者临床病理指标的关系。通过对随访资料的分析，比较不同TMEM79蛋白表达水平患者的生存情况差异，评估TMEM79蛋白对Ia-IIa期HCC术后的影响。结果：TMEM79蛋白在HCC组织中的阳性表达率高于非肿瘤组织(χ²=4.270；P<0.05)，TMEM79蛋白在不同分化程度的HCC组织间的表达水平差异具有统计学意义(χ²=8.902；P<0.05)；TMEM79阳性与阴性表达组间的总生存期(OS)及无进展生存期(PFS)差异具有统计学意义(P<0.01)。经Cox回归分析，TMEM79蛋白阳性表达是Ia-IIa期HCC术后复发转移的危险因素[HR=2.001，95%CI(1.152，3.476)，P<0.05]。HCC团片状型组织学形态[HR=3.090，95%CI(1.317，7.273)，P<0.05]及TMEM79蛋白阳性表达[HR=3.323，95%CI(1.652，6.683)，P<0.05]是影响Ia-IIa期HCC术后生存的危险因素。结论：TMEM79蛋白在HCC组织中的表达与HCC分化程度相关；TMEM79蛋白阳性表达影响术后患者的预后，可作为Ia-IIa期HCC患者术后复发转移及生存情况的预测因素。

关键词: 肝细胞癌, 跨膜蛋白79, 预后, 临床指标

Abstract: OBJECTIVE：To investigate expression of the transmembrane protein 79(TMEM79) in hepatocellular carcinoma(HCC)，and to analyze its correlations with clinicopathological characteristics and prognosis of the patients. METHODS：From May 2011 to August 2017，clinicopathological data of 95 patients in the Meizhou People--s Hospital with HCC who received radical surgical treatment were collected. Expression levels of TMEM79 were evaluated using immunohistochemistry. Relationships between TMEM79 expressions and clinicopathological factors were analyzed using the χ² test. Kaplan-Meier method and Log-rank test were performed to analyze the survival time. Cox proportional risk regression model was used to analyze prognostic factors. RESULTS：The expression levels of TMEM79 in HCC was significantly correlated with the differentiation degree of HCC (χ²=8.902；P<0.05). The overall survival times (OS) and the progression-free survival times (PFS) of the negative expression group was significantly prolonged comparing with the positive expression group (P<0.01). Positive expression of TMEM79 was a risk factor for postoperative recurrences and metastases in patients with stage Ⅰa-Ⅱa [HR=2.001，95%CI (1.152，3.476)，P<0.05]. Histological morphology with mass form predominantly [HR=3.090，95%CI(1.317，7.273)，P<0.05] and the positive expression levels of TMEM79 [HR=3.323，95%CI (1.652，6.683)，P<0.05] were independent factors affecting postoperative PFS and OS in HC C patients with stageⅠa-Ⅱa(P<0.05). CONCLUSION：Expression of the TMEM79 protein in HCC tissue was related to the degrees of HCC differentiation. The positive expression levels of TMEM79 were related to poor prognosis. Positive expression levels of TMEM79 protein can possibly be used as a predictive factor for postoperative HCC patients with stage Ⅰa-Ⅱa.

Key words: hepatocellular carcinoma, transmembrane protein 79, prognosis, clinical features

中图分类号:

R730.2

朱文标, 丘波, 谢寿城, 肖焕钦, 刘高敏. 跨膜蛋白79在肝细胞癌中的表达及临床意义[J]. 癌变·畸变·突变, 2023, 35(6): 426-430.

ZHU Wenbiao, QIU bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 426-430.

参考文献

[1] 国家卫生健康委员会医政医管局. 国家卫生健康委办公厅关于印发原发性肝癌诊疗指南(2022年版)的通知[EB/OL].(2022-01-20). http://www.nhc.gov.cn/yzygj/s7659/202201/a01ceb75c62b486fa459e36ba0fdfdbc.shtml.
[2] 南月敏, 高沿航, 王荣琦, 等. 原发性肝癌二级预防共识(2021年版)[J]. 临床肝胆病杂志, 2021, 37(3):532-542.
[3] 中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)原发性肝癌诊疗指南-2022[M]. 北京:人民卫生出版社, 2022.
[4] SCHMIT K, MICHIELS C. TMEM proteins in cancer:a review[J]. Front Pharmacol, 2018, 9:1345.
[5] OβHURLEY G, BUSCH C, FAGERBERG L, et al. Analysis of the human prostate-specific proteome defined by transcriptomics and antibody-based profiling identifies TMEM79 and ACOXL as two putative, diagnostic markers in prostate cancer[J]. PLoS One, 2015, 10(8):e0133449.
[6] MARX S, DAL MASO T, CHEN J W, et al. Transmembrane (TMEM) protein family members:poorly characterized even if essential for the metastatic process[J]. Semin Cancer Biol, 2020, 60:96-106.
[7] JIANG X Y, WANG L, LIU Z Y, et al. TMEM48 promotes cell proliferation and invasion in cervical cancer via activation of the Wnt/β-catenin pathway[J]. J Recept Signal Transduct Res, 2021, 41(4):371-377.
[8] TIAN J, SUN L, WAN L S, et al. TMEM44 as a novel prognostic marker for kidney renal clear cell carcinoma is associated with tumor invasion, migration and immune infiltration[J]. Biochem Genet, 2023. doi:10.1007/s10528-023-10466-x.
[9] YE Z H, XIA Y Q, LI L, et al. Effect of transmembrane protein 100 on prostate cancer progression by regulating SCNN1D through the FAK/PI3K/AKT pathway[J]. Transl Oncol, 2023, 27:101578.
[10] CHEN J P, WANG D D, CHEN H Q, et al. TMEM196 inhibits lung cancer metastasis by regulating the Wnt/β-catenin signaling pathway[J]. J Cancer Res Clin Oncol, 2023, 149(2):653-667.
[11] ZHANG X L, HE Y, JIANG Y, et al. TMEM229A suppresses non-small cell lung cancer progression via inactivating the ERK pathway[J]. Oncol Rep, 2021, 46(2):176.
[12] DUAN J C, QIAN Y W, FU X H, et al. TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma[J]. Aging, 2021, 13(4):5585-5606.
[13] ZHANG L, LIU S Y, YANG X, et al. TMEM206 is a potential prognostic marker of hepatocellular carcinoma[J]. Oncol Lett, 2020, 20(5):174.
[14] CHEN D S, LOU Y C, LU J, et al. Characterization of the clinical significance and immunological landscapes of a novel TMEMs signature in hepatocellular carcinoma and the contribution of TMEM201 to hepatocarcinogenesis[J]. Int J Mol Sci, 2023, 24(12):10285.
[15] EMRICK J J, MATHUR A, WEI J, et al. Tissue-specific contributions of Tmem79 to atopic dermatitis and mast cell-mediated histaminergic itch[J]. Proc Natl Acad Sci U S A, 2018, 115(51):E12091-E12100.
[16] HE S, LYU F Q, LOU L X, et al. Anti-tumor activities of Panax quinquefolius saponins and potential biomarkers in prostate cancer[J]. J Ginseng Res, 2021, 45(2):273-286.

跨膜蛋白79在肝细胞癌中的表达及临床意义

Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	许金花, 李静静, 吴国峰, 任亚俊, 王雪, 张骞云. 非小细胞肺癌患者血清miR-146a与TNF-α、Treg的相关性及其对预后判断的价值[J]. 癌变·畸变·突变, 2023, 35(6): 462-466.
[2]	杨上英, 黄明翔, 许德新, 刘加夫, 陈新富. DNAJB4与非小细胞肺癌免疫细胞浸润和患者预后的相关性分析[J]. 癌变·畸变·突变, 2023, 35(6): 467-472.
[3]	高榴, 禹莉. 线粒体转录因子A在肿瘤发生发展中作用的研究进展[J]. 癌变·畸变·突变, 2023, 35(6): 485-488.
[4]	呙文静, 邓慧, 宋萍, 张孟贤. 转化生长因子β诱导蛋白在胶质瘤中的表达及生物学功能[J]. 癌变·畸变·突变, 2023, 35(5): 341-348.
[5]	韦来凤, 洪超群, 陈柳伊, 许镒洧, 伍方财. 实验室炎症相关指标的列线图对预测舌鳞状细胞癌患者手术预后的价值[J]. 癌变·畸变·突变, 2023, 35(5): 366-373.
[6]	杨程晴, 崔永辉, 郑紫恒. 结肠癌患者血清中miR-653-5p的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(4): 261-265.
[7]	刘瑞雪, 张力为. 腺苷酸活化蛋白激酶在哈萨克族食管鳞癌组织中的表达及意义[J]. 癌变·畸变·突变, 2023, 35(4): 285-291.
[8]	刘颖, 王蕊, 郭晓, 董律吏, 张艳, 赵银环, 杜芸. 肺腺癌胸腔积液DNA倍体异常与EGFR突变的关系及其对患者预后的影响[J]. 癌变·畸变·突变, 2023, 35(3): 178-182,186.
[9]	王平, 王华勇, 王浩, 雷大军. 骨肉瘤患者血清外泌体中miR-193a和miR-21-5p表达水平及其临床意义[J]. 癌变·畸变·突变, 2023, 35(3): 197-201.
[10]	黄利丹, 吴月明, 王亚帝, 谭琦. EGFR突变型肺腺癌组织中VEGF-A蛋白的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(2): 116-120.
[11]	谭健华, 赖姚圳, 唐丽华, 周莉. 2种不同疗法对晚期上皮性卵巢癌的疗效及患者预后影响因素分析[J]. 癌变·畸变·突变, 2023, 35(2): 131-138.
[12]	胡学义, 沈丰, 武伦, 苏才武, 魏涧. SPON2在甲状腺乳头状癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(1): 9-14.
[13]	许浩, 胡碧川, 邹伟, 段雅斌. 行根治术的Ⅲ期胃癌患者预后影响因素分析[J]. 癌变·畸变·突变, 2023, 35(1): 30-36.
[14]	路大鹏, 赵卫林, 王玉强, 路洪超, 魏双平. 食管癌生存随访调查及列线图预后预测模型的建立[J]. 癌变·畸变·突变, 2023, 35(1): 37-42.
[15]	李燕, 董经茹, 魏媛媛, 张金艳. 极光激酶A在宫颈鳞状细胞癌患者血清中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(6): 421-428.